Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world effectiveness and safety of hydroxyurea in adults with hemoglobin SC disease: A retrospective cohort study in Quebec, Canada

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLaurianne CharetteUniversité de MontréalMPMarilou PoitrasUniversity of Ottawa

Discussion

Loading...

Member takes

Overview

Retrospective cohort study demonstrates hydroxyurea improves outcomes in sickle cell disease, suggesting a favorable safety profile and need for patient education.

Key Points

  • To evaluate the effectiveness and safety of hydroxyurea in adults with hemoglobin SC disease.
  • Retrospective cohort study at CHUM from January 2010 to July 2025.
  • Analysis of patients with HbSC initiating hydroxyurea for at least 12 months.
  • Efficacy measured as change in frequency of vaso-occlusive crises pre- and post-treatment.
  • Hydroxyurea reduced VOCC by 56% from 0.57 to 0.25 annually (p = 0.0015).
  • Most participants experienced mild adverse events; thrombocytopenia occurred in 32.7%.
  • 27.3% of patients discontinued treatment, citing lack of awareness or adverse effects.

Cite This Study

Charette et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e348https://doi.org/10.1182/blood-2025-410
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin <scp>SC</scp> disease: A real‐world study in Quebec2026
  2. 2Is hydroxyurea treatment associated with an increased risk of malignancy in sickle cell disease? a propensity-matched analysis of 27,854 patients in the real world2025
  3. 3Systematic intensification of red cell exchange with hydroxyurea decreased the transfusion burden in patients with sickle cell disease: A single-center retrospective cohort study2025 · 1 citations
  4. 4Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence‐guided care2026
  5. 5Outcomes of pregnancies in sickle cell patients treated with hydroxyurea : Findings from the escort-HU cohort studies2025